«Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies». J. Clin. Oncol. 29. PMID21220604. doi:10.1200/JCO.2010.29.87112
«The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes». Blood. 114. PMID19357394. doi:10.1182/blood-2009-03-209262
«Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies». J. Clin. Oncol. 29. PMID21220604. doi:10.1200/JCO.2010.29.8711
«A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera». Nature. 434. PMID15793561. doi:10.1038/nature03546
«Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis». Cancer Cell. 7. PMID15837627. doi:10.1016/j.ccr.2005.03.023
«Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation». The Journal of Molecular Diagnostics. 18. PMID27449473. doi:10.1016/j.jmoldx.2016.05.006
«Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study». Lancet. 366. PMID16325696. doi:10.1016/S0140-6736(05)67785-9
«Some speculations on the myeloproliferative syndromes». Blood. 6. PMID14820991
«Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies». J. Clin. Oncol. 29. PMID21220604. doi:10.1200/JCO.2010.29.87112
«The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes». Blood. 114. PMID19357394. doi:10.1182/blood-2009-03-209262
«Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies». J. Clin. Oncol. 29. PMID21220604. doi:10.1200/JCO.2010.29.8711
«A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera». Nature. 434. PMID15793561. doi:10.1038/nature03546
«Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis». Cancer Cell. 7. PMID15837627. doi:10.1016/j.ccr.2005.03.023
«Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation». The Journal of Molecular Diagnostics. 18. PMID27449473. doi:10.1016/j.jmoldx.2016.05.006
«Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study». Lancet. 366. PMID16325696. doi:10.1016/S0140-6736(05)67785-9